Genitourinary Cancers | Specialty

Bladder Cancer: Immunotherapy in the Perioperative Setting

March 16th 2017

Combination Trials in Advanced Bladder Cancer

March 16th 2017

Immunotherapy Toxicity Management in Bladder Cancer

March 16th 2017

Update on Durvalumab for Metastatic Bladder Cancer

March 16th 2017

Chemotherapy Following Immunotherapy in Bladder Cancer

March 16th 2017

Activity of Immunotherapy in the Frontline Setting

March 16th 2017

Bladder Cancer: Real-World Experience With Immunotherapy

March 16th 2017

FDA Approval of Atezolizumab for Advanced Bladder Cancer

March 16th 2017

PD-L1 Expression in Bladder Cancer

March 16th 2017

Prognostic Subgroups in Advanced Bladder Cancer

March 16th 2017

Historic Perspective on Treatment of Bladder Cancer

March 16th 2017

Researcher Aims to Advance Immunotherapy Impact in Bladder Cancer

March 15th 2017

Arlene O. Siefker-Radtke, MD, discusses the exciting advances in the bladder cancer field, why researchers should move past PD-L1 as a biomarker, and what combinations can be expected to move through the pipeline next.

Expert Sees Checkpoint and PARP Inhibitors Building on mCRPC Success

March 14th 2017

Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.

Researchers Aim to Further Enhance Value of RT in Prostate Cancer

March 14th 2017

Seungtaek L. Choi, MD, discussed the latest developments with radiation therapy in prostate cancer.

Dr. McDermott Discusses the Future of Immune Checkpoints in RCC

March 13th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the future of immunotherapies in the treatment of patients with kidney cancer.

Gomella Discusses Ongoing Progress With Genetic Testing in Prostate Cancer

March 11th 2017

Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.

Dr. Jonasch on Alternative Sunitinib Scheduling for mRCC

March 11th 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).

Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer

March 10th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.

Dr. Linehan on Gene Mutations in Papillary Kidney Cancer

March 10th 2017

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses gene mutations in papillary kidney cancer.

"Richness of Choices" Available in Kidney Cancer, But Patient Selection Is Key

March 9th 2017

Eric Jonasch, MD, speaks on the evolving choices for patients with renal cell carcinoma in the first- and second-line settings, as well as the remaining challenges in the field.